학술논문
A randomized controlled trial of a multicomponent online stress reduction intervention in inflammatory bowel disease
Document Type
article
Author
Farhad Peerani; Makayla Watt; Kathleen P Ismond; Reid Whitlock; Lindsy Ambrosio; Naomi Hotte; Nicholas Mitchell; Robert J Bailey; Karen Kroeker; Levinus A Dieleman; Jesse Siffledeen; Allen Lim; Karen Wong; Brendan P Halloran; Daniel C Baumgart; Lorian Taylor; Maitreyi Raman; Karen L Madsen; Puneeta Tandon
Source
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Subject
Language
English
ISSN
1756-2848
17562848
17562848
Abstract
Background: Psychological stress negatively impacts inflammatory bowel disease (IBD) outcomes. Patients have prioritized access to online interventions; yet, the data on these have been limited by mixed in-person/online interventions, low adherence, and non-randomized controlled trial (RCT) design. Objectives: We assessed the efficacy of and adherence to a 12-week online multicomponent stress reduction intervention in IBD. Design: This is a RCT. Methods: Adult participants on stable IBD medical therapy with elevated stress levels from four centers were randomized to intervention or control groups. Intervention participants received a 12-week online program including a weekly yoga, breathwork and meditation video (target 2–3 times/week), a weekly cognitive behavioral therapy/positive psychology informed video activity, and weekly 10-min check-ins by a study team member. Control participants received weekly motivational messages by email. All patients received standard of care IBD therapy. The primary outcome was Cohen’s Perceived Stress Scale (PSS). Secondary outcomes evaluated mental health, resilience, health-related quality of life (HRQoL), symptom indices, acceptability, adherence, and inflammatory biomarkers. Analysis of covariance was used to determine between-group differences. Results: Of 150 screened patients, 101 were randomized to the intervention ( n = 49) and control ( n = 52) groups (mean age: 42.5 ± 14.1 years; M:F 1:3, 48% with ulcerative colitis and 52% with Crohn’s disease). The between-group PSS improved by 22.4% (95% confidence interval, 10.5–34.3, p